Deciphera Pharmaceuticals Announces Oral Presentation of Results From Motion Pivotal Phase 3 Study of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor (Tgct) at 2024 Asco Annual Meeting and Online Publication in Lancet
deciphera pharmaceuticals宣佈在2024年ASCO年會上口服Vimseltinib在滑膜腫瘤（Tgct）患者中的MOTION關鍵3期研究結果的口頭報告，並在《柳葉刀》雜誌上進行在線發表